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The membrane may be considered as a simple sieve membrane. All the "pores" of it are as permeable to creatinine, inulin, and glucose as they are to water and so all these substances pass across it at the same rate and their concentrations are the same on either side.
A small number of "pores" are known to be permeable to hemoglobin so there must be a fall in the number of pores permeable to molecules in the range between these two sizes. As the number of pores available for filtration decreases with increase in molecular size, so the area available for filtration and the rate of filtration must fall.
The distribution of pore size will be indicated by the graph obtained by plotting the rate of filtration at the glomerulus as represented by the slope of the line U/G against molecular weight (Fig. 2) . The results are preliminary but they indicate that all the pores are permeable to molecules of weight about 7,000, then there is a rapid fall to 20% permeable at 25,000 and a flattening out of the curve to 6 % permeable to molecules about 38,000.
These results can only apply to dextran which has a markedly asymmetric molecule. Many factors such as molecular shape and charge and changes in glomerular dynamics, e.g. increased filtration fraction may well affect the movement of molecules across the glomerular membrane. We are looking forward to examining these possibilities and to attempting to estimate the range of pore size of the normal and diseased glomerulus in the human subject.
Experiments with Dextran Sulphate as an Anticoagulant By K. WALTON, M.D.
Department of Pathological Studies, University ofBirmingham BERGSTROM demonstrated in 1936 that the sulphuric esters of polysaccharides have a heparin-like anticoagulant activity. It was shown by Astrup et al. (1944 Astrup et al. ( , 1946 ) that certain of these compounds were unsuitable for clinical use because they precipitated fibrinogen, agglutinated platelets and caused death from internal bleeding with large dosages.
Gronwall, Ingelman and Mosimann (1945) synthesized three esters of dextrans of varying molecular weight and reported that these all showed toxic properties similar to those of other sulphonated polysaccharides, and concluded that molecular weight was not an important factor in determining the toxicity of these compounds. From the data later furnished by Ingelman (1947) it was possible to infer that his least toxic preparation was appreciably larger in molecular weight than heparin. Accordingly, a range of compounds extending in molecular weight both above and below those prepared by Ingelman was prepared and examined. It was found that when the starting-material (dextran) was below a certain critical molecular weight, the sulphuric ester prepared from it was free from the undesirable properties described above and no more toxic than heparin itself in experimental animals. This compound is shortly to be submitted to therapeutic trial.
Dextran sulphates.-From Table I it can be seen that the dextran sulphates of molecular weight 35,000 and above behaved differently from those of molecular weight 20,000 and less. The first group (hereafter called "large molecular weight" dextran sulphates) behaved similarly though in varying degree, in causing (1) Precipitation of fibrinogen, (2) Agglutination of platelets, (3) Deposition of granular material in reticulo-endothelial cells. The second group ("Small molecular weight" dextran sulphates) were free from these properties.
Large molecular weight dextran sulphates.-The toxicity of these compounds was found to be dependent upon their tendency to precipitate fibrinogen. When this occurred in plasma in vitro the platelets became adherent to, and entrained in the precipitate, forming clumps. This explained the thrombocytopenia and fibrinogenopenia which occurred in vivo in rats to whom the material was given intravenously. Subsequent phagocytosis of the particles of this precipitate accounted for the appearance of granular material in the reticulo-endothelial cells -of the liver, spleen and bope-marrow of animals killed between one hour and twenty-eight days after the injection of large molecular weight dextran sulphate. Dextran sulphate, like heparin, gives a marked metachromatic reaction with toluidine blue in vitro and it was found that this granular material in the reticulo-endothellal cells gave a similarly conspicuous reaction when sections were stained with toluidine blue and examined.
These properties of the large molecular weight compounds made them obviously unsuitable for therapeutic use and from this standpoint they were discarded.
Small molecular weight dextran sulphates.-On the other hand, the small molecular weight dextran sulphates, like heparin, had no effect on platelets in vivo or in vitro, nor, when administered to experimental animals did they give rise to deposits in reticuloendothelial cells. Their properties, in these respects, are contrasted with the large molecular weight compounds in Table I . One typical batch of this material when assayed against International Standard Heparin had an activity of 17-20 units/mg. It was found to be effective by parenteral injection only. The effect of intravenous administration of varying doses on the clotting time in rabbits is seen from Fig. 1 With dosages up to 500 mg./kg. body-weight, no toxic effects were observed in the mouse, rat, rabbit, dog or monkey. With certain batches transient reactions were observed in the guinea-pig but these did not prove fatal. Careful histological examination of the liver, spleen, kidneys, skeletal and heart muscle, skin, bone-marrow, lymph nodes, endocrines and central nervous system showed no parenchymal damage though this was looked for after single injections, repeated injections and over periods from one hour to three months after the last injection. Intravenous administration produced no effect on the blood pressure, pulse-rate or respiratory rate. At anticoagulant concentrations, a negligible effect was produced on the erythrocyte sedimentation rate, and since the material has no osmotic effect on the red cells, it was found that the ordinary himatological estimations were not interfered with. No effects were observed on the motility or phagocytic activity ofwhite cells in vitro or in vivo. Attempts to produce allergic sensitivity to dextran sulphate were not successful.
Mode of action.-It seems probable that dextran sulphate owes its anticoagulant properties to the strong electro-negative charge upon its acidic groups, since, like heparin, its action is opposed by strongly basic substances such as protamine. For its action, dextran sulphate, like heparin, requires the presence of a co-factor in serum or plasma. In the presence of this co-factor its action is that of an antithrombin.
Summary and conclusion.-The sulphuric esters of dextrans of molecular weight less than 20,000 are free from the undesirable toxic effects of previously described sulphonated polysaccharides. One such compound is being submitted to clinical trials and, if found satisfactory, may serve as a synthetic analogue of heparin. It should be possible to produce this material at considerably lower 'cost than heparin.
